Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2000-2010

ABSTRACT

RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as alemtuzumab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving methotrexate, cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them (called graft-versus-tumor effect). Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect. PURPOSE: This phase I/II trial is studying the side effects of giving fludarabine together with cyclophosphamide and to see how well they work in treating patients who are undergoing donor stem cell transplant for B-cell chronic lymphocytic leukemia or Waldenström's macroglobulinemia. Detailed Description OBJECTIVES: Primary - Determine the feasibility and safety of induction therapy comprising fludarabine and cyclophosphamide followed by allogeneic stem cell transplantation in patients with high-risk B-cell chronic lymphocytic leukemia or lymphoplasmocytic lymphoma (Waldenstrom's macroglobulinemia). Secondary - Determine the incidence and kinetics of clinical and molecular remissions in patients treated with this regimen. - Determine event-free and overall survival of patients treated with this regimen. - Determine the duration of clinical and molecular remission in relation to the underlying cytogenetic deviation in patients treated with this regimen. - Determine the kinetics and extent of lympho-hematopoietic donor chimerism in patients treated with this regimen. OUTLINE: This is a multicenter, open-label, nonrandomized, pilot study. - Cytoreductive therapy: Patients receive up to 3 courses of cytoreductive therapy comprising fludarabine IV and cyclophosphamide IV on days 1-3 (with or without rituximab IV on day 1). Patients refractory to fludarabine-containing therapy may receive alemtuzumab IV for 12 weeks OR any other cytotoxic salvage regimen for cytoreduction. - Conditioning regimen: Patients receive 1 of the following conditioning regimens*: NOTE: *Patients who did not achieve partial response after cytoreductive therapy receive regimen 3. - Regimen 1: Patients receive fludarabine IV and cyclophosphamide IV on days -7 to -3. If stem cells are collected from an unrelated donor, patients also receive anti-thymocyte globulin (ATG) IV on days -4 to -1. - Regimen 2: Patients undergo total-body irradiation on day -9. Patients then receive alemtuzumab IV on days -8 to -4 and fludarabine IV and cyclophosphamide IV on days -6 to -2. - Regimen 3: Patients receive fludarabine IV on days -7 to -3, busulfan IV or orally on days -7 to -5, and cyclophosphamide IV on days -3 to -2. If stem cells are collected from an unrelated donor, patients also receive ATG on days -3 to -1. - Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo allogeneic PBSCT on day 0. Patients receive filgrastim (G-CSF) subcutaneously daily starting on day 5 and continuing until blood count recover. - Graft-versus-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV beginning on day -1 and continuing until approximately day 100. Patients treated with conditioning regimen 1 or 3 also receive methotrexate IV on days 1, 3, and 6 OR oral mycophenolate mofetil twice daily on days 0-50. Patients with evidence of residual disease at least 4 weeks after completion of cyclosporine undergo donor lymphocyte infusion (DLI). - DLI: The donor T-lymphocytes are collected from the PBSCT donor without prior G-CSF mobilization. Patients receive DLI every 8 weeks in the presence of residual disease and the absence of GVHD. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study. More... »

URL

https://clinicaltrials.gov/show/NCT00281983

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as alemtuzumab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving methotrexate, cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them (called graft-versus-tumor effect). Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect. PURPOSE: This phase I/II trial is studying the side effects of giving fludarabine together with cyclophosphamide and to see how well they work in treating patients who are undergoing donor stem cell transplant for B-cell chronic lymphocytic leukemia or Waldenstr\u00f6m's macroglobulinemia.\n\nDetailed Description\nOBJECTIVES: Primary - Determine the feasibility and safety of induction therapy comprising fludarabine and cyclophosphamide followed by allogeneic stem cell transplantation in patients with high-risk B-cell chronic lymphocytic leukemia or lymphoplasmocytic lymphoma (Waldenstrom's macroglobulinemia). Secondary - Determine the incidence and kinetics of clinical and molecular remissions in patients treated with this regimen. - Determine event-free and overall survival of patients treated with this regimen. - Determine the duration of clinical and molecular remission in relation to the underlying cytogenetic deviation in patients treated with this regimen. - Determine the kinetics and extent of lympho-hematopoietic donor chimerism in patients treated with this regimen. OUTLINE: This is a multicenter, open-label, nonrandomized, pilot study. - Cytoreductive therapy: Patients receive up to 3 courses of cytoreductive therapy comprising fludarabine IV and cyclophosphamide IV on days 1-3 (with or without rituximab IV on day 1). Patients refractory to fludarabine-containing therapy may receive alemtuzumab IV for 12 weeks OR any other cytotoxic salvage regimen for cytoreduction. - Conditioning regimen: Patients receive 1 of the following conditioning regimens*: NOTE: *Patients who did not achieve partial response after cytoreductive therapy receive regimen 3. - Regimen 1: Patients receive fludarabine IV and cyclophosphamide IV on days -7 to -3. If stem cells are collected from an unrelated donor, patients also receive anti-thymocyte globulin (ATG) IV on days -4 to -1. - Regimen 2: Patients undergo total-body irradiation on day -9. Patients then receive alemtuzumab IV on days -8 to -4 and fludarabine IV and cyclophosphamide IV on days -6 to -2. - Regimen 3: Patients receive fludarabine IV on days -7 to -3, busulfan IV or orally on days -7 to -5, and cyclophosphamide IV on days -3 to -2. If stem cells are collected from an unrelated donor, patients also receive ATG on days -3 to -1. - Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo allogeneic PBSCT on day 0. Patients receive filgrastim (G-CSF) subcutaneously daily starting on day 5 and continuing until blood count recover. - Graft-versus-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV beginning on day -1 and continuing until approximately day 100. Patients treated with conditioning regimen 1 or 3 also receive methotrexate IV on days 1, 3, and 6 OR oral mycophenolate mofetil twice daily on days 0-50. Patients with evidence of residual disease at least 4 weeks after completion of cyclosporine undergo donor lymphocyte infusion (DLI). - DLI: The donor T-lymphocytes are collected from the PBSCT donor without prior G-CSF mobilization. Patients receive DLI every 8 weeks in the presence of residual disease and the absence of GVHD. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.", 
    "endDate": "2010-07-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00281983", 
    "keywords": [
      "Pilot Project", 
      "allogeneic stem cell transplantation", 
      "alkylating agent", 
      "high risk", 
      "B-Cell Chronic Lymphocytic Leukemia", 
      "rationale", 
      "bone marrow transplant", 
      "stop", 
      "cancer cell", 
      "patient", 
      "immune system", 
      "Tissue Donor", 
      "stem cell", 
      "monoclonal antibody", 
      "alemtuzumab", 
      "substance", 
      "harming normal cell", 
      "bone marrow", 
      "Erythrocyte", 
      "leukocyte", 
      "Blood Platelet", 
      "transplanted cell", 
      "immune response", 
      "body", 
      "normal cell", 
      "methotrexate", 
      "Cyclosporine", 
      "mycophenolate mofetil", 
      "Transplant", 
      "graft-versus-tumor effect", 
      "infusion", 
      "donor lymphocyte infusion", 
      "phase I/II trial", 
      "side effect", 
      "fludarabine", 
      "cyclophosphamide", 
      "stem cell transplant", 
      "Waldenstrom Macroglobulinemia", 
      "Determine", 
      "feasibility", 
      "safety", 
      "induction therapy", 
      "lymphoma", 
      "incidence", 
      "kinetics", 
      "remission", 
      "regimen", 
      "overall survival", 
      "duration", 
      "relation", 
      "cytogenetics", 
      "donor chimerism", 
      "outline", 
      "multicenter", 
      "therapy", 
      "rituximab", 
      "salvage", 
      "conditioning regimen", 
      "note", 
      "partial response", 
      "unrelated donor", 
      "Antilymphocyte Serum", 
      "body irradiation", 
      "busulfan", 
      "peripheral blood stem cell", 
      "Granulocyte Colony-Stimulating Factor", 
      "blood count", 
      "graft-versus-host-disease", 
      "prophylaxis", 
      "conditioning", 
      "evidence", 
      "residual disease", 
      "completion", 
      "T lymphocyte", 
      "mobilization", 
      "absence", 
      "study treatment", 
      "accrual"
    ], 
    "name": "Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00281983"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00002.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.412753.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411937.9", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410718.b", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412468.d", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411984.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410712.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411941.8", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411097.a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.414216.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411339.d", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.5253.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.459389.a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.10423.34", 
        "type": "Organization"
      }
    ], 
    "startDate": "2000-06-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1182/blood-2012-11-469627", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003236006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2010-03-275420", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009414333"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2008.96", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017004338", 
          "https://doi.org/10.1038/leu.2008.96"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.14219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035504501"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2017-04-775841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090748389"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00281983"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00281983'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00281983'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00281983'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00281983'


 

This table displays all metadata directly associated to this object as RDF triples.

143 TRIPLES      16 PREDICATES      112 URIs      87 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00281983 schema:about anzsrc-for:3048
2 anzsrc-for:3103
3 anzsrc-for:3142
4 schema:description RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as alemtuzumab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving methotrexate, cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them (called graft-versus-tumor effect). Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect. PURPOSE: This phase I/II trial is studying the side effects of giving fludarabine together with cyclophosphamide and to see how well they work in treating patients who are undergoing donor stem cell transplant for B-cell chronic lymphocytic leukemia or Waldenström's macroglobulinemia. Detailed Description OBJECTIVES: Primary - Determine the feasibility and safety of induction therapy comprising fludarabine and cyclophosphamide followed by allogeneic stem cell transplantation in patients with high-risk B-cell chronic lymphocytic leukemia or lymphoplasmocytic lymphoma (Waldenstrom's macroglobulinemia). Secondary - Determine the incidence and kinetics of clinical and molecular remissions in patients treated with this regimen. - Determine event-free and overall survival of patients treated with this regimen. - Determine the duration of clinical and molecular remission in relation to the underlying cytogenetic deviation in patients treated with this regimen. - Determine the kinetics and extent of lympho-hematopoietic donor chimerism in patients treated with this regimen. OUTLINE: This is a multicenter, open-label, nonrandomized, pilot study. - Cytoreductive therapy: Patients receive up to 3 courses of cytoreductive therapy comprising fludarabine IV and cyclophosphamide IV on days 1-3 (with or without rituximab IV on day 1). Patients refractory to fludarabine-containing therapy may receive alemtuzumab IV for 12 weeks OR any other cytotoxic salvage regimen for cytoreduction. - Conditioning regimen: Patients receive 1 of the following conditioning regimens*: NOTE: *Patients who did not achieve partial response after cytoreductive therapy receive regimen 3. - Regimen 1: Patients receive fludarabine IV and cyclophosphamide IV on days -7 to -3. If stem cells are collected from an unrelated donor, patients also receive anti-thymocyte globulin (ATG) IV on days -4 to -1. - Regimen 2: Patients undergo total-body irradiation on day -9. Patients then receive alemtuzumab IV on days -8 to -4 and fludarabine IV and cyclophosphamide IV on days -6 to -2. - Regimen 3: Patients receive fludarabine IV on days -7 to -3, busulfan IV or orally on days -7 to -5, and cyclophosphamide IV on days -3 to -2. If stem cells are collected from an unrelated donor, patients also receive ATG on days -3 to -1. - Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo allogeneic PBSCT on day 0. Patients receive filgrastim (G-CSF) subcutaneously daily starting on day 5 and continuing until blood count recover. - Graft-versus-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV beginning on day -1 and continuing until approximately day 100. Patients treated with conditioning regimen 1 or 3 also receive methotrexate IV on days 1, 3, and 6 OR oral mycophenolate mofetil twice daily on days 0-50. Patients with evidence of residual disease at least 4 weeks after completion of cyclosporine undergo donor lymphocyte infusion (DLI). - DLI: The donor T-lymphocytes are collected from the PBSCT donor without prior G-CSF mobilization. Patients receive DLI every 8 weeks in the presence of residual disease and the absence of GVHD. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.
5 schema:endDate 2010-07-01T00:00:00Z
6 schema:keywords Antilymphocyte Serum
7 B-Cell Chronic Lymphocytic Leukemia
8 Blood Platelet
9 Cyclosporine
10 Determine
11 Erythrocyte
12 Granulocyte Colony-Stimulating Factor
13 Pilot Project
14 T lymphocyte
15 Tissue Donor
16 Transplant
17 Waldenstrom Macroglobulinemia
18 absence
19 accrual
20 alemtuzumab
21 alkylating agent
22 allogeneic stem cell transplantation
23 blood count
24 body
25 body irradiation
26 bone marrow
27 bone marrow transplant
28 busulfan
29 cancer cell
30 completion
31 conditioning
32 conditioning regimen
33 cyclophosphamide
34 cytogenetics
35 donor chimerism
36 donor lymphocyte infusion
37 duration
38 evidence
39 feasibility
40 fludarabine
41 graft-versus-host-disease
42 graft-versus-tumor effect
43 harming normal cell
44 high risk
45 immune response
46 immune system
47 incidence
48 induction therapy
49 infusion
50 kinetics
51 leukocyte
52 lymphoma
53 methotrexate
54 mobilization
55 monoclonal antibody
56 multicenter
57 mycophenolate mofetil
58 normal cell
59 note
60 outline
61 overall survival
62 partial response
63 patient
64 peripheral blood stem cell
65 phase I/II trial
66 prophylaxis
67 rationale
68 regimen
69 relation
70 remission
71 residual disease
72 rituximab
73 safety
74 salvage
75 side effect
76 stem cell
77 stem cell transplant
78 stop
79 study treatment
80 substance
81 therapy
82 transplanted cell
83 unrelated donor
84 schema:name Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia
85 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00281983
86 schema:sdDatePublished 2019-03-07T15:22
87 schema:sdLicense https://scigraph.springernature.com/explorer/license/
88 schema:sdPublisher N48b3f8bea8e64da3a7bc28e83f2a133f
89 schema:sponsor https://www.grid.ac/institutes/grid.10423.34
90 https://www.grid.ac/institutes/grid.410712.1
91 https://www.grid.ac/institutes/grid.410718.b
92 https://www.grid.ac/institutes/grid.411097.a
93 https://www.grid.ac/institutes/grid.411339.d
94 https://www.grid.ac/institutes/grid.411937.9
95 https://www.grid.ac/institutes/grid.411941.8
96 https://www.grid.ac/institutes/grid.411984.1
97 https://www.grid.ac/institutes/grid.412468.d
98 https://www.grid.ac/institutes/grid.412753.6
99 https://www.grid.ac/institutes/grid.414216.4
100 https://www.grid.ac/institutes/grid.459389.a
101 https://www.grid.ac/institutes/grid.5253.1
102 schema:startDate 2000-06-01T00:00:00Z
103 schema:subjectOf sg:pub.10.1038/leu.2008.96
104 https://doi.org/10.1111/bjh.14219
105 https://doi.org/10.1182/blood-2010-03-275420
106 https://doi.org/10.1182/blood-2012-11-469627
107 https://doi.org/10.1182/blood-2017-04-775841
108 schema:url https://clinicaltrials.gov/show/NCT00281983
109 sgo:license sg:explorer/license/
110 sgo:sdDataset clinical_trials
111 rdf:type schema:MedicalStudy
112 N48b3f8bea8e64da3a7bc28e83f2a133f schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
115 rdf:type schema:DefinedTerm
116 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
117 rdf:type schema:DefinedTerm
118 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
119 rdf:type schema:DefinedTerm
120 sg:pub.10.1038/leu.2008.96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017004338
121 https://doi.org/10.1038/leu.2008.96
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1111/bjh.14219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035504501
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1182/blood-2010-03-275420 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009414333
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1182/blood-2012-11-469627 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003236006
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1182/blood-2017-04-775841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090748389
130 rdf:type schema:CreativeWork
131 https://www.grid.ac/institutes/grid.10423.34 schema:Organization
132 https://www.grid.ac/institutes/grid.410712.1 schema:Organization
133 https://www.grid.ac/institutes/grid.410718.b schema:Organization
134 https://www.grid.ac/institutes/grid.411097.a schema:Organization
135 https://www.grid.ac/institutes/grid.411339.d schema:Organization
136 https://www.grid.ac/institutes/grid.411937.9 schema:Organization
137 https://www.grid.ac/institutes/grid.411941.8 schema:Organization
138 https://www.grid.ac/institutes/grid.411984.1 schema:Organization
139 https://www.grid.ac/institutes/grid.412468.d schema:Organization
140 https://www.grid.ac/institutes/grid.412753.6 schema:Organization
141 https://www.grid.ac/institutes/grid.414216.4 schema:Organization
142 https://www.grid.ac/institutes/grid.459389.a schema:Organization
143 https://www.grid.ac/institutes/grid.5253.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...